Trial Profile
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Brain cancer; Cognition disorders
- Focus Therapeutic Use
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.